OPKO & Entera Bio To Develop First Oral GLP-1/Glucagon Dual Agonist
18/3 00:07
(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic disorders....